Sanger Sequencing Service Market: Current Analysis and Forecast (2022-2028)

Sanger Sequencing Service Market: Current Analysis and Forecast (2022-2028)

Sanger sequencing is one of the oldest DNA sequencing methods which utilizes dideoxynucleotides to sequence DNA. It is frequently used for the sequencing of plasmid DNA, polymerase chain reaction (PCR) products, and bacterial artificial chromosomes (BAC) and is the most preferred choice for mutation detection. The sanger sequencing service market is growing tremendously due to its wide range of applications in the diagnosis of chronic diseases, unmet need for personalized medicine, and surge in the prevalence of rare genetic diseases.

The Sanger Sequencing Service Market is expected to grow at a strong CAGR of 10% during the forecast period owing to the surge in the prevalence of various cancers and rising awareness regarding the diagnosis of cancer. The American Cancer Society Journal estimates that approximately 140,690 people in the U.S. are diagnosed with cancer each year and that 103,250 people pass away from cancer each year. In addition, the World Health Organization (WHO) cites cancer as the second leading cause of death worldwide. Moreover, the increase in the prevalence of rare genetic diseases and the surge in the demand for personalized medicine are also positively impacting the growth of the market.

• Based on application, the market is segmented into diagnostics, biomarkers and cancer, reproductive health, personalized medicine, forensics, and others. The biomarkers and cancer segment held the dominant share of the market in 2021 which is mainly due to the surge in the prevalence of cancer, high demand for advanced sanger systems and services for the identification of cancer biomarkers, and rising investment for ongoing cancer research. Apart from this, sanger sequencing can also be used in drug development to identify potential targets for cancer therapies. Moreover, strategic developments undertaken by market players are also anticipated to bolster the market's growth over the analysis period. For instance, in March 2022, Vela Diagnostics released new next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens.
• On the basis of end user, the market is segmented into academics and governmental organizations, pharmaceutical companies, hospitals & clinics, and others. Pharmaceutical companies are anticipated to grow with a high CAGR during the forecast period. This is mainly attributed to the surge in the number of research projects across a wide range of applications such as drug discovery and development, diagnosis, human health mapping, population studies, and others.
• For a better understanding of the market adoption of the Sanger Sequencing Service industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market in 2021. The market is driven by increasing demand for personalized medicine, genomics research, and agricultural and food sciences. Moreover, the market is highly competitive, with several key players offering a range of sequencing services to academic and commercial customers. In addition to this, companies are rapidly expanding their services in North America, which will also have a positive impact on the growth of the market during the forecast period. For instance, in August 2022, Source Bioscience launched sanger sequencing service in San Diego to support life science researchers with market leading genomic services.
• Some of the major players operating in the market include Microsynth AG; Thermo Fisher Scientific, Inc.; Azenta Life Sciences; GenHunter Corporation; LGC Biosearch Technologies; Laragen, Inc; STARSEQ GmbH; Medisupport SA; Quintara; and ciGenom Labs Pvt. Ltd.